Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 2.
doi: 10.1007/s12094-025-03958-2. Online ahead of print.

Previous history of solid tumor in patients presenting tuberculosis: a multicenter retrospective study in a low-tuberculosis-incidence area

Miguel Borregón  1 , Paula Rodríguez  2 , Beatriz Grau  2 , Asia Ferrández  2 , Elia Sirvent  3 , María-Montserrat Ruiz-García  3 , Elia Martínez  4 , Javier-David Benítez-Fuentes  2
Affiliations

Previous history of solid tumor in patients presenting tuberculosis: a multicenter retrospective study in a low-tuberculosis-incidence area

Miguel Borregón et al. Clin Transl Oncol. .

Abstract

Purpose: This study aims to describe the prevalence of previous solid tumor and prior systemic cancer therapy in patients newly diagnosed with active tuberculosis (TB) in a low-Tuberculosis-incidence region.

Methods: A retrospective multicenter study was conducted from 2018 to 2023 across two tertiary hospitals in southeastern Spain, covering a population of approximately 341,000 inhabitants. Patients with culture-confirmed TB were identified through electronic health records. Demographic data, cancer history, systemic cancer therapy, and comorbidities were analyzed to assess any association between active TB and previous solid tumors.

Results: Among 87 patients diagnosed with active TB (incidence rate: 5.1 per 100,000 inhabitants per year), 64.4% were male, with a median age of 48 years (range: 0-85). Only four patients (4.6%) had a history of solid tumor, none of whom had received systemic cancer therapy or radiotherapy prior to active TB diagnosis. Statistical analysis showed no significant difference between TB patients with a history of cancer and the general population, and there were no significant associations between gender, country of origin, or systemic cancer therapy.

Conclusion: In this low-incidence TB region, previous medical history of solid tumor among active TB patients is marginal. Solid tumor history does not behave as a strong risk factor for active TB development. In this region, routine latent TB screening in solid cancer patients is not supported by scientific evidence. Routine TB screening may lead to unnecessary interventions and increase healthcare costs. Further research in different epidemiological settings is recommended to validate these findings and inform global clinical practice guidelines.

Keywords: Guidelines; Latent TB screening; Solid tumor; Systemic cancer therapy; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: All the authors of the manuscript declare there was no conflict of interest. Informed consent: Informed consent was obtained from all participants. Ethical Approval: This article does not contain any studies with human participants or animals.

References

    1. Bagcchi S. WHO’s global tuberculosis report 2022. Lancet Microbe. 2023;4(1): e20. https://doi.org/10.1016/S2666-5247(22)00359-7 . - DOI - PubMed
    1. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10): e1002152. https://doi.org/10.1371/journal.pmed.1002152 . - DOI - PubMed - PMC
    1. Rapoport BL, Cooksley T, Johnson DB, Anderson R, Shannon VR. Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev Clin Pharmacol. 2021;14(3):295–313. https://doi.org/10.1080/17512433.2021.1884067 . - DOI - PubMed
    1. Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, et al. Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis. Clin Infect Dis. 2017;64(5):635–44. https://doi.org/10.1093/cid/ciw838 . - DOI - PubMed
    1. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, HawleY DK, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043–54. https://doi.org/10.1200/JCO.18.00374 . - DOI - PubMed

LinkOut - more resources